

9-1-2011

BMPR-II is Dispensable for Formation of the Limb Skeleton.

Laura W Gamer

Kunikazu Tsuji

Karen Cox

Luciane P Capelo

Jonathan W. Lowery Ph.D.

Marian University - Indianapolis, jlowery@marian.edu

See next page for additional authors

Follow this and additional works at: https://mushare.marian.edu/com_fp

 Part of the [Medicine and Health Sciences Commons](#)

Recommended Citation

Gamer LW, Tsuji K, Cox K, Capelo LP, Lowery J, Beppu H, Rosen V. "BMPR-II is dispensable for formation of the limb skeleton." *Genesis*. 2011 Sep;49(9):719-24. PMID: 21538804.

This Article is brought to you for free and open access by the College of Osteopathic Medicine at MUShare. It has been accepted for inclusion in Faculty Publications and Research by an authorized administrator of MUShare. For more information, please contact emandity@marian.edu.

Authors

Laura W Gamer, Kunikazu Tsuji, Karen Cox, Luciane P Capelo, Jonathan W. Lowery Ph.D., Hideyuki Beppu, and Vicki Rosen

LETTER

BMPR-II is Dispensable for Formation of the Limb Skeleton

Laura W. Gamer,^{1*} Kunikazu Tsuji,² Karen Cox,¹ Luciane P. Capelo,¹ Jonathan Lowery,¹ Hideyuki Beppu,³ and Vicki Rosen¹

¹Department of Developmental Biology, Harvard School of Dental Medicine, Boston, Massachusetts

²Department of Orthopedic Surgery, Tokyo Medical and Dental University, Tokyo, Japan

³Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts

Received 3 March 2011; Accepted 15 April 2011

Summary: Initiation of BMP signaling is dependent upon activation of Type I BMP receptor by constitutively active Type II BMP receptor. Three Type II BMP receptors have been identified; *Acvr2a* and *Acvr2b* serve as receptors for BMPs and for activin-like ligands whereas *BMPR-II* functions only as a BMP receptor. As BMP signaling is required for endochondral ossification and loss of either *Acvr2a* or *Acvr2b* is not associated with deficits in limb development, we hypothesized that *BMPR-II* would be essential for BMP signaling during skeletogenesis. We removed *BMPR-II* from early limb mesoderm by crossing *BMPR-II* floxed mice with those carrying the *Prx1-Cre* transgene. Mice lacking limb expression of *BMPR-II* have normal skeletons that could not be distinguished from control littermates. From these data, we conclude that *BMPR-II* is not required for endochondral ossification in the limb where loss of *BMPR-II* may be compensated by BMP utilization of *Acvr2a* and *Acvr2b*. *genesis* 49:719–724, 2011. © 2011 Wiley-Liss, Inc.

Signaling by members of the bone morphogenetic protein (BMP) family has been shown to be critical for many aspects of limb development and endochondral bone formation. BMPs transduce their signals by bringing together Type I and II serine/threonine kinase receptors to form heterotetrameric complexes. Within this complex, the constitutively active kinase domain of the Type II receptor is key to initiating the BMP signal transduction cascade: its close proximity to the kinase domain of the Type I receptor promotes Type I receptor phosphorylation (Shi and Massague, 2003). Once activated, the Type I receptor is able to phosphorylate and activate BMP-

specific R-Smads, increasing their affinity for Smad4. The resulting R-Smad/Smad4 complexes travel to the nucleus where they affect a wide variety of transcriptional responses directly by binding to Smad binding elements, or indirectly through interactions with DNA-binding transcription factors and histone-modifying proteins (Miyazono *et al.*, 2005).

Both too much BMP and too little BMP signaling result in skeletal abnormalities, consistent with the idea that BMP signaling is a highly regulated process. While many investigators have focused on the regulatory roles of BMPs, BMP antagonists, Type I BMP receptors, and BMP-specific Smads (Devlin *et al.*, 2003; Kamiya *et al.*, 2008; Ovchinnikov *et al.*, 2006; Retting *et al.*, 2009; Selever *et al.*, 2004; Yoon *et al.*, 2005), few studies have examined the requirement for each of the three Type II BMP receptors present during skeletogenesis. It has been reported that global loss of *Acvr2a* or *Acvr2b*, Type II receptors common to both the BMP and activin/myostatin pathways has no obvious effect on formation of the embryonic skeleton (Miyazono *et al.*, 2005; Oh and Li, 1997), allowing us to hypothesize that *BMPR-II* is the dominant Type II receptor utilized for skeletogenesis. Here we show the surprising result that loss of *BMPR-II* in the early limb has no effect on skeletal patterning or endochondral ossification.

* Correspondence to: Laura W. Gamer, Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA, USA.

E-mail: laura_gamer@hsdm.harvard.edu

Published online 2 May 2011 in

Wiley Online Library (wileyonlinelibrary.com).

DOI: 10.1002/dvg.20761




FIG. 1. Loss of *BMPR-II* has no effect on early limb development. (a,b) Whole mount in situ hybridization of E11.5 control and *BMPR-II*^{CKO} limb buds showing deletion of *BMPR-II* from limb mesenchyme. (c) Western blot analysis showing loss of *BMPR-II* protein in conditional knockout limbs at E12. β -actin was used as a loading control. (d,e) Alcian blue/Fast red stained sections of forelimb buds of E12.5 control and *BMPR-II*^{CKO} embryos. (f) Western blot of extracts from control and *BMPR-II*^{CKO} E12 limb buds ($n = 3$) using anti-pSmad1/5/8 antibody to evaluate BMP signaling and anti-p-Smad2/3 antibody to evaluate TGF- β signaling. Smad1 and Smad2/3 antibodies were used to detect total R-Smad protein as a control. (g) Nanostring analysis of E12 limb bud mRNA from control and *BMPR-II*^{CKO} embryos showing no changes in the levels of *Acvr2a* or *Acvr2b*. Values are expressed as number of molecules per 200 ng of total RNA.

RESULTS AND DISCUSSION

Deletion of *BMPR-II* by *Prx1-Cre*

As global deletion of *BMPR-II* in mice results in embryonic lethality during gastrulation (Beppu *et al.*, 2000), we used Cre recombinase driven by a *Prx1* enhancer (Logan *et al.*, 2002) to conditionally remove *BMPR-II* from limb mesenchyme. *Prx1-Cre* heterozygotes were mated with mice homozygous for a conditional allele of *BMPR-II* engineered by flanking Exons 4 and 5 (which included the transmembrane domain and a portion of the kinase domain) with lox P sites (Beppu *et al.*, 2005) to generate *BMPR-II*^{CKO} mice. We confirmed the inactivation of *BMPR-II* by *Prx1-Cre* recombination at early limb bud stages using whole mount in situ hybridization. Figure 1a,b demonstrates the efficient removal of *BMPR-II* transcripts from the limb mesenchyme at E11.5. *BMPR-II* was still detected in the limb ectoderm where the *Prx1-Cre* transgene is inactive. *BMPR-II* deletion from the limb was further verified at the protein level by western blot. As illustrated in Figure 1c, *BMPR-II* protein in E12 limb bud lysates was sig-

nificantly reduced in the conditional knockout limbs compared to those of littermate controls.

Loss of *BMPR-II* Has No Effect on Early Limb Development

At E11.5, *BMPR-II*^{CKO}, and *Prx1-Cre*⁺ control embryos were morphologically similar with no apparent differences in the shape, size, or pattern of the limbs (Fig. 1a,b and data not shown). Detailed histological analysis revealed no alterations in the formation or organization of the developing cartilages at E12.5 in the absence of *BMPR-II* (Fig. 1d,e), while quantitative polymerase chain reaction (QPCR) analysis of RNA from E12.5 *BMPR-II*^{CKO} and control limb buds showed no significant changes in early cartilage markers (*Sox9* and *Col2a1*, data not shown). To assess if loss of *BMPR-II* results in changes in BMP signaling, we collected limb buds from E12 embryos and analyzed them by western blot for alterations in p-Smad1/5/8 or p-Smad2/3 levels. As seen in Figure 1f, we found no changes in either BMP or TGF- β /activin signaling in *BMPR-II*^{CKO} limbs when compared to control limbs. Since BMP ligands




FIG. 2. (a) Alizarin Red and Alcian Blue staining of whole skeletons from E16 control and *BMPR-II*^{CKO} mice. No obvious skeletal patterning or development differences are detected. (b,c) Toluidine blue staining of distal femurs from E16 mouse embryos showing no obvious differences between control and *BMPR-II*^{CKO} bones. (d,e) p-Smad1/5/8 immunohistochemistry of E16 humerus from control and *BMPR-II*^{CKO} mice showing no significant changes in BMP R-Smad signaling.

could utilize *Acvr2a* and *Acvr2b* to maintain adequate signaling levels, we isolated RNA from E12 limb buds and used the Nanostring nCounter technology (Geiss *et al.*, 2008) to examine changes in transcript levels for these receptors. As shown in Figure 1g, no significant differences were seen in the mRNA levels of *Acvr2a* or *Acvr2b* in *BMPR-II*^{CKO} limbs. From these data we conclude that *Acvr2a* and *Acvr2b* present in the early limb most likely compensate for loss of *BMPR-II* and are able to provide the level of BMP signaling necessary for early skeletogenesis. In addition, these data suggest that *BMPR-II* is not uniquely required for the first steps of limb patterning or early cartilage formation.

Deletion of *BMPR-II* Results in No Significant Changes in the Formation of Long Bones

Next we examined *BMPR-II*^{CKO} mice at later stages of skeletal development to see if *BMPR-II* was required for the subsequent steps of endochondral ossification. Alizarin Red and Alcian Blue-stained skeletons from E15.5 embryos showed no obvious changes in the shape, size, pattern, or formation of the long bones lacking *BMPR-II* (Fig. 2a). These observations were confirmed by histological analysis of hindlimbs from E16 *BMPR-II*^{CKO} and control embryos that showed the absence of *BMPR-II* did not change the timing or extent of cartilage or bone formation or impact joint morphogenesis (Fig. 2b,c and data not shown). As endothelial or pulmonary artery smooth muscle cells with *BMPR-II* mutations exhibit increased cell death and failed growth suppression (Morrell, 2006), we checked for similar alterations in cell proliferation or apoptosis in *BMPR-II*^{CKO} femurs but saw no differences between conditional knockout and control mice (data not shown). Next, we performed immunohistochemistry for p-Smad1/5/8 on humeri from E16 *BMPR-II*^{CKO} mice and saw no changes in BMP signaling in chondrocytes, perichondrial, perisoteal, or bone cells (Fig. 2d,e). Finally, we examined *BMPR-II* conditional knockout mice at birth to look for any defects or fractures in the long bone. Alizarin Red and

Alcian Blue stained skeletal preparation of forelimbs and hindlimbs from *BMPR-II*^{CKO} newborns (NB) showed no significant alterations in bone formation (Fig. 3a,b), and detailed histological analysis of newborn *BMPR-II*^{CKO} long bones confirmed the lack of significant changes in growth plate, trabecular bone or cortical bone in the absence of *BMPR-II* (Fig. 3c,h and data not shown). We verified these finding by performing in situ hybridization for chondrocyte and bone markers on humeri from NB *BMPR-II*^{CKO} mice and saw no alterations in the levels or localization of *Col2a1*, *Col10a1*, or *Osteopontin* (Fig. 3d-f,i-k). These data were further confirmed by using QPCR analysis of RNA from NB *BMPR-II*^{CKO} femurs (Fig. 3m). In addition, Von Kossa staining of femurs from NB mice revealed no changes in bone mineralization with loss of *BMPR-II* (Fig. 3g,l). Taken together, these data confirm our initial observation that loss of *BMPR-II* from the early limb does not impair the level of BMP signaling necessary for endochondral ossification.

Loss of Individual Type II Receptors Does Not Have Significant Effects on Endochondral Bone Formation

To confirm the finding that global loss of either of the Type II BMP receptors, *Acvr2a* or *Acvr2b* has little effect on the limb skeleton (Matzuk *et al.*, 1995; Oh and Li, 1997), we collected femurs from *Acvr2a* and *Acvr2b* knockout mice at birth and performed a detailed histological analysis. We found, in agreement with previous studies, that loss of either *Acvr2a* or *Acvr2b* did not have a significant effect on bone or joint formation when compared to wild type controls (see Fig. 4). Taken as a whole the results obtained by analyzing the limbs of mice lacking each individual Type II BMP receptor is in keeping with the idea that these Type II receptors can compensate for one another during limb skeletogenesis and endochondral bone formation.

Our data, although surprising, are in agreement with two previous studies on the function of *BMPR-II* in skel-




FIG. 3. Long bones of BMPR-II^{CKO} mice have no significant defects in endochondral bone formation. (a,b) Whole mount forelimbs and hindlimbs from newborn control and BMPR-II^{CKO} mice stained with Alizarin Red and Alcian Blue. No fractures or obvious defects in bone shape, size or formation have developed. Radioactive in situ hybridization analysis of markers for chondrogenesis and osteogenesis on humeri of newborn control (c-f) and BMPR-II^{CKO} mice (h-k). No changes are detected in *Col2a1*, *Col10a1*, or *osteopontin*. (g,i) Von Kossa stained sections of distal femur from newborn mice showing no significant differences in mineralization between control and BMPR-II^{CKO} animals. (m) QPCR analysis of chondrocyte and bone markers in control and BMPR-II^{CKO} femurs at birth. No statistically significant changes were detected.

etal tissues. Mice homozygous for a hypomorphic allele of *BMPR-II* die at mid-gestation from cardiovascular abnormalities but display only a mild axial skeletal phenotype of delayed ossification of cervical vertebrae and interparietal bone and loss of the 13th pair of ribs (Delot *et al.*, 2003). Transgenic mice engineered to express a C-terminal truncated form of *BMPR-II* in osteoblast lineage cells also only exhibited a mild bone phenotype of delayed mineralization of the calvaria and vertebrae at birth (Yang *et al.*, 2010). Taken as a whole, these data allow us to conclude that BMPR-II is not necessary for endochondral ossification and the requirement for BMP signaling may be compensated for by BMPs acting through *Acvr2a* and *Acvr2b*.

METHODS

Mouse Strains

Mice in which Exons 4 and 5 of *BMPR-II* was flanked with lox P sites (BMPR-II^{fl/fl}) were obtained from Dr. Hideyuki Beppu, Massachusetts General Hospital, Boston, MA. The creation and genotyping of the conditional floxed *BMPR-II* allele has been described previously

(Beppu *et al.*, 2005). The *Prx1-cre* allele has also been described previously (Logan *et al.*, 2002). BMPR-II^{fl/fl} mice were mated to transgenic mice that express Cre under the control of the *Prx1* promoter to create mice in which *BMPR-II* is deleted in the early limb mesenchyme (BMPR-II^{CKO}).

Acvr2a knockout mice were kindly provided by Dr. Martin Matzuk (Baylor College of Medicine, Houston, TX) and described previously (Matzuk *et al.*, 1995). *Acvr2b* mice were kindly provided by Dr. Paul Oh (University of Florida College of Medicine, Gainesville, FL) and described previously (Oh and Li, 1997). All mouse strains used in this study were on a C57BL/6 × 129/SvEv mixed genetic background.

Whole Mount and Section In Situ Hybridization

Whole mount in situ hybridization was performed with digoxigenin-labeled antisense mouse *BMPR-II* probe (Beppu *et al.*, 2000) as previously described (Brent *et al.*, 2003). Section in situ hybridization with radiolabeled probes was performed as described (Bandyopadhyay *et al.*, 2006). ³⁵S-labeled complementary RNA probes were transcribed from plasmids encoding




FIG. 4. Femurs from *Acvr2a* and *Acvr2b* knockout mice have no significant alterations in bone formation. Toluidine blue stained sections of femurs from newborn wild type (a) and *Acvr2a*^{-/-} mice (b) and newborn wild type (c) and *Acvr2b*^{-/-} mice (d).

Col2a1 (Kohno *et al.*, 1984), *Col10a1* (Jacenko *et al.*, 1993), and osteopontin (Oldberg *et al.*, 1986).

Skeletal Preparations

For whole skeletal analysis, staged embryos (the day the vaginal plug was observed was considered embryonic day 0.5 - E0.5) and newborn mice were prepared and stained with Alizarin Red and Alcian Blue to identify mineralized bone and cartilage as previously described (McLeod, 1980).

Histological and Immunohistochemical Analysis

For histology, limbs were dissected and fixed in 4% paraformaldehyde, decalcified in EDTA/PVP when necessary, paraffin embedded, and sectioned. Slides were stained with Alcian Blue/Fast Red, Toluidine Blue and Von Kossa using standard methods. For immunofluorescence, sections were microwaved in 10 mM citrate buffer pH 6.0 for antigen retrieval, blocked with 0.5% bovine serum albumin (BSA) and incubated with phospho-Smad1/5/8 (Cell Signaling Technology) overnight

at 4°C. The slides were then washed and incubated overnight at 4°C with Alexa-Fluor-555-conjugated rabbit secondary antibody (Invitrogen). Apoptosis was evaluated using the In Situ Cell Death Detection kit, POD (Roche). Cell proliferation was analyzed by proliferation cell nuclear antigen (PCNA) staining using a PCNA staining kit (Zymed). The PCNA positive or TUNEL positive cells were individually counted from at least four sections of comparable regions of the distal femur growth plate of three control and three *BMPR-II*^{CKO} littermate pairs at E16.

Western Blots

Western blots were performed on lysates from limb buds excised from E12.5 control and *BMPR-II*^{CKO} embryos. Lysates were resolved on Novex Tris Glycine gels (Invitrogen) and transferred to Amersham Hybond ECL nitrocellulose membranes (GE Healthcare). After blocking in 10% milk, the following primary antibodies were applied overnight at 4°C: anti-C-terminal phospho-Smad1/5/8 (Cell Signaling), anti-C-terminal phospho-Smad2/3 (Cell Signaling), and anti-Smad1 (Cell Signaling) rabbit polyclonal antibodies; anti-*BMPR-II* (BD Biosciences), anti-Smad2/3 (BD Biosciences), and anti- β -actin (Sigma) mouse monoclonal antibodies. Primary antibodies were applied in 5% milk, except for the detection of phospho-specific isoforms which were applied in 5% BSA. Appropriate species-specific goat polyclonal secondary antibodies (anti-mouse: Kirkegaard & Perry Laboratories and anti-rabbit: Cell Signaling) were utilized. Immunoblots were developed by chemiluminescence using Western Lightning (Perkin Elmer) and exposed to Amersham Hyperfilm ECL (GE Healthcare).

Quantitative PCR

Total RNA was extracted from E12 embryonic limb buds and from femurs of newborn mice using Trizol reagents (Invitrogen) according to the manufacturer's protocol. RNA from E12 limb buds was analyzed using Nanostring nCounter, a novel technology able to measure directly the number of specific mRNA molecules without PCR amplification (Geiss *et al.*, 2008). To use this ultra-sensitive technology, a CodeSet containing specific probe pairs (reporter and capture probes) for 50 genes was customized. This CodeSet was incubated at 65°C for 19 h with 200 ng of RNA. Immediately after incubation, the samples were washed and the purified target/probe complexes were immobilized in a cartridge for data collection. The results are expressed in number of molecules per 200 ng of total RNA. For Quantitative RT-PCR (QPCR), cDNA was transcribed from 1 μ g of total RNA from NB femurs with random primer using the Transcriptor First Strand cDNA Synthesis Kit (Roche). QPCR was performed by using the

Roche LightCycler 480 Real-time PCR system with probe-based detection (Universal Probe Library; Roche). Values were normalized to β -actin using the $2^{-\Delta\Delta Ct}$ method (Livak and Schmittgen, 2001). Experiments were performed in triplicate.

LITERATURE CITED

- Bandyopadhyay A, Tsuji K, Cox K, Harfe BD, Rosen V, Tabin CJ. 2006. Genetic analysis of the roles of BMP2, BMP4, and BMP7 in limb patterning and skeletogenesis. *PLoS Genet* 2:e216.
- Beppu H, Kawabata M, Hamamoto T, Chytil A, Minowa O, Noda T, Miyazono K. 2000. BMP type II receptor is required for gastrulation and early development of mouse embryos. *Dev Biol* 221:249–258.
- Beppu H, Lei H, Bloch KD, Li E. 2005. Generation of a floxed allele of the mouse BMP type II receptor gene. *Genesis* 41:133–137.
- Brent AE, Schweitzer R, Tabin CJ. 2003. A somitic compartment of tendon progenitors. *Cell* 113:235–248.
- Delot EC, Bahamonde ME, Zhao M, Lyons KM. 2003. BMP signaling is required for septation of the outflow tract of the mammalian heart. *Development* 130:209–220.
- Devlin RD, Du Z, Pereira RC, Kimble RB, Economides AN, Jorgetti V, Canalis E. 2003. Skeletal overexpression of noggin results in osteopenia and reduced bone formation. *Endocrinology* 144:1972–1978.
- Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, Fell HP, Ferree S, George RD, Grogan T, James JJ, Maysuria M, Mitton JD, Oliveri P, Osborn JL, Peng T, Ratcliffe AL, Webster PJ, Davidson EH, Hood L, Dimitrov K. 2008. Direct multiplexed measurement of gene expression with color-coded probe pairs. *Nat Biotechnol* 26:317–325.
- Jacenko O, LuValle P, Solum K, Olsen BR. 1993. A dominant negative mutation in the alpha 1 (X) collagen gene produces spondylometaphyseal defects in mice. *Prog Clin Biol Res* 383B:427–436.
- Kamiya N, Ye L, Kobayashi T, Lucas DJ, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y. 2008. Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. *J Bone Miner Res* 23:2007–2017.
- Kohn K, Martin GR, Yamada Y. 1984. Isolation and characterization of a cDNA clone for the amino-terminal portion of the pro-alpha 1(II) chain of cartilage collagen. *J Biol Chem* 259:13668–13673.
- Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-(\Delta\Delta Ct)}$ Method. *Methods* 25:402–408.
- Logan M, Martin JF, Nagy A, Lobe C, Olson EN, Tabin CJ. 2002. Expression of Cre Recombinase in the developing mouse limb bud driven by a *Prxl* enhancer. *Genesis* 33:77–80.
- Matzuk MM, Kumar TR, Bradley A. 1995. Different phenotypes for mice deficient in either activins or activin receptor type II. *Nature* 374:356–360.
- McLeod MJ. 1980. Differential staining of cartilage and bone in whole mouse fetuses by alcian blue and alizarin red S. *Teratology* 22:299–301.
- Miyazono K, Maeda S, Imamura T. 2005. BMP receptor signaling: Transcriptional targets, regulation of signals, and signaling cross-talk. *Cytokine Growth Factor Rev* 16:251–263.
- Morrell NW. 2006. Pulmonary hypertension due to BMPR2 mutation: A new paradigm for tissue remodeling? *Proc Am Thorac Soc* 3:680–686.
- Oh SP, Li E. 1997. The signaling pathway mediated by the type IIB activin receptor controls axial patterning and lateral asymmetry in the mouse. *Genes Dev* 11:1812–1826.
- Oldberg A, Franzen A, Heinegard D. 1986. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. *Proc Natl Acad Sci USA* 83:8819–8823.
- Ovchinnikov DA, Selever J, Wang Y, Chen YT, Mishina Y, Martin JF, Behringer RR. 2006. BMP receptor type IA in limb bud mesenchyme regulates distal outgrowth and patterning. *Dev Biol* 295:103–115.
- Retting KN, Song B, Yoon BS, Lyons KM. 2009. BMP canonical Smad signaling through Smad1 and Smad5 is required for endochondral bone formation. *Development* 136:1093–1104.
- Selever J, Liu W, Lu MF, Behringer RR, Martin JF. 2004. *Bmp4* in limb bud mesoderm regulates digit pattern by controlling AER development. *Dev Biol* 276:268–279.
- Shi Y, Massague J. 2003. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell* 113:685–700.
- Yang C, Yang L, Wan M, Cao X. 2010. Generation of a mouse model with expression of bone morphogenetic protein type II receptor lacking the cytoplasmic domain in osteoblasts. *Ann N Y Acad Sci* 1192:286–291.
- Yoon BS, Ovchinnikov DA, Yoshii I, Mishina Y, Behringer RR, Lyons KM. 2005. *Bmpr1a* and *Bmpr1b* have overlapping functions and are essential for chondrogenesis in vivo. *Proc Natl Acad Sci USA* 102:5062–5067.